The China medical imaging market size is expected to reach USD 2.7 billion by 2030, growing at a CAGR of 6.2% during the forecast period, based on a new report by Grand View Research, Inc. The growth of the market is attributed to several factors such as the increasing prevalence of chronic diseases, technological advancements to improve the turnaround time, favorable reimbursement policies, growing government funding & initiatives, rising geriatric population, and expanding healthcare infrastructure.
The growing burden of chronic diseases & rising geriatric population in China has propelled the demand for advanced medical imaging technologies, thereby boosting the market growth. For instance, according to the report published on PubMed stating ‘Cardiovascular Health and Diseases in China 2021’, the cases of patients suffering from coronary heart disease, stroke, pulmonary heart disease, heart failure, rheumatic heart disease, congenital heart disease, atrial fibrillation, and hypertension is 13 million, 11.39 million, 5.00 million, 8.90 million, 2.50 million, 2.00 million, 4.87 million, and 245 million, respectively.
The aforementioned information is suggesting the growing prevalence of cardiovascular diseases & cancer and increasing awareness about early diagnosis are expected to contribute to lucrative growth opportunities during the forecast period. Additionally, enabling early disease detection, accurate diagnosis, and effective disease management, medical imaging plays a crucial role in improving patient outcomes and enhancing the overall quality of healthcare in the context of chronic diseases. The market also benefits from a growing awareness of the importance of early disease detection and preventive healthcare.
Manufacturers in the China medical imaging industry are also contributing to its growth by expanding their product portfolios through strategic collaborations, product launches, and mergers & acquisitions. For example, in January 2023, GE Healthcare, a leading player in the industry, announced its acquisition of Caption Health, Inc., an AI healthcare provider specializing in clinical applications for early disease diagnosis using ultrasound scans. Such partnerships and advancements demonstrate the market's commitment to innovation and its focus on providing state-of-the-art solutions for early disease detection and improved patient care.
Request a free sample copy or view report summary: China Medical Imaging Market Report
Based on modality, the ultrasound segment held the largest market share of 29.06% in 2022 owing to enhanced capabilities of this type such as treating gallbladder disease and guiding a needle for biopsy or tumor treatment
The Computed Tomography (CT) segment is expected to showcase the fastest CAGR during the forecast period
Based on end-use, the hospital segment had the largest market share of 34.94% in 2022, owing to the rising demand for more accurate diagnostic tools
Technological advancements are also anticipated to drive the growth of the advanced wound care market in the forthcoming years
Some of the major market players are GE HealthCare, Siemens Healthcare GmbH, Koninklijke Philips N.V., CANON MEDICAL SYSTEMS CORPORATION, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Shanghai United Imaging Healthcare Co., LTD
Grand View Research has segmented the China medical imaging market based on modality and end-use:
China Medical Imaging Modality Outlook (Revenue, USD Million, 2018 - 2030)
X-ray
Radiography
Fluoroscopy
Mammography
Ultrasound
2D
3D/4D
Doppler
Computed Tomography (CT)
High slice
Mid slice
Low slice
Cone beam
Magnetic Resonance Imaging (MRI)
Low - strength
Mid - strength
High - strength
Nuclear Medicine
SPECT
PET
China Medical Imaging End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Diagnostic Imaging Centers
Others
List of Key Players in the China Medical Imaging Market
GE HealthCare
Siemens Healthcare GmbH
Koninklijke Philips N.V.
Canon Medical Systems Corporation
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Shanghai United Imaging Healthcare Co., Ltd.
"The quality of research they have done for us has been excellent..."